+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Research Report on China's Anlotinib Hydrochloride Market, 2021-2025

  • PDF Icon

    Report

  • 40 Pages
  • November 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5504592

Anlotinib hydrochloride is a novel small molecule multi-target tyrosine kinase inhibitor that effectively inhibits kinases like VEGFR, PDGFR, FGFR, and c-Kit with anti-tumor angiogenesis and tumor growth inhibition effects.





The drug is a new Category 1.1 antitumor drug developed by the Chinese pharmaceutical company Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Its clinical trials are already underway for a variety of cancers, including non-small cell lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, medullary thyroid cancer, differentiated thyroid cancer, and esophageal squamous cancer.


Anlotinib hydrochloride was approved for marketing under the trade name FuKeWei® by the NMPA on May 9, 2018, for the third-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The fast time to market anlotinib hydrochloride was made possible by the Chinese government’s support for accelerated evaluation and approval of innovative drugs.


According to the market research, as of September 2021, anlotinib has been approved in China for four indications: (1) advanced NSCLC (2) soft tissue sarcomas (3) small cell lung cancer (4) advanced or metastatic medullary thyroid cancer.


In 2020, there were 4.57 million new cancer cases in China, 820,000 of which were lung cancer cases. Lung cancer is mainly divided into small cell lung cancer and non-small cell lung cancer (NSCLC), and the latter accounts for about 80-85% among all patients with lung cancer, most of which are diagnosed as locally advanced or metastatic disease.


Soft tissue sarcomas are a group of rare cancers with a low incidence that account for only 1% of all malignancies. But it is characterized by high evolution possibility, poor prognosis, high insidiousness, and inconspicuous early symptoms, making it extremely difficult to treat clinically.


According to the analyst's estimation, there were about 220,000 new cases of thyroid cancer in China in 2020, among which medullary thyroid carcinoma (MTC) accounts for about 2%-4%. MTC is more likely to have malignant evolution and distant metastasis, and the treatment may not impose good effects for patients with advanced stage.


According to the analyst’s market research, the sales value of anlotinib in the Chinese market was approximately CNY922 million (USD142 million) in 2020, with a CAGR of 444% from 2018 to 2020. Generic drugs of anlotinib from other Chinese pharmaceutical companies are expected to be on the market around 2024, so China’s anlotinib market will remain fully occupied by Chia Tai Tianqing Pharmaceutical’s product till 2025.


The analyst expects that China’s anlotinib market will continue to grow from 2021 to 2025 as new cancer cases are expected to increase in China due to environmental pollution and lifestyle changes.


Topics Covered:

  • Impact of COVID-19 on China’s Anlotinib Hydrochloride Market
  • The Incidence of Cancers in China
  • Development Environment of Anlotinib Hydrochloride in China
  • Sales Volume of Anlotinib Hydrochloride in China
  • Sales Volume and Value of Anlotinib Hydrochloride in China by Region
  • Major Anlotinib Hydrochloride Manufacturers in China and Their Market Shares
  • Sales Price of Anlotinib Hydrochloride in China
  • Major Anlotinib Hydrochloride Producers in China
  • Prospects of China’s Anlotinib Hydrochloride Market, 2021-2025
Frequently Asked Questions about the Chinese Anlotinib Hydrochloride Market

What is the estimated value of the Chinese Anlotinib Hydrochloride Market?

The Chinese Anlotinib Hydrochloride Market was estimated to be valued at CNY 31.12 Million in 2018.

What is the growth rate of the Chinese Anlotinib Hydrochloride Market?

The growth rate of the Chinese Anlotinib Hydrochloride Market is 84.9%, with an estimated value of CNY 2295.43 Million by 2025.

What is the forecasted size of the Chinese Anlotinib Hydrochloride Market?

The Chinese Anlotinib Hydrochloride Market is estimated to be worth CNY 2295.43 Million by 2025.

Who are the key companies in the Chinese Anlotinib Hydrochloride Market?

Key companies in the Chinese Anlotinib Hydrochloride Market include Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (FuKeWei®).

Table of Contents

1 Relevant Concept of Anlotinib Hydrochloride
1.1 Indications of Anlotinib Hydrochloride
1.2 Development of China’s Anlotinib Hydrochloride Market
1.3 Governmental Approval of Anlotinib Hydrochloride in China
1.4 The Impact of COVID-19 on China’s Anlotinib Hydrochloride Market
2 Sales of Anlotinib Hydrochloride in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Anlotinib Hydrochloride in China by Dosage Form, 2016-2020
2.3.1 Capsules
2.3.2 Other Dosage Forms
3 Analysis of Major Anlotinib Hydrochloride Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.2.1 Company Profile
3.2.2 Sales of Anlotinib Hydrochloride in China
4 Sales Price of Anlotinib Hydrochloride of Different Companies in China, 2020-2021
4.1 Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (FuKeWei®)
4.2 Other Key Players
5 Prospects of China’s Anlotinib Hydrochloride Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information of Anlotinib Hydrochloride in China
Chart Sales Value of Anlotinib Hydrochloride in China, 2016-2020
Chart Sales Volume of Anlotinib Hydrochloride in China, 2016-2020
Chart Sales Value of Anlotinib Hydrochloride Capsules in China, 2016-2020
Chart Sales Value and Volume of Anlotinib Hydrochloride (of Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China, 2016-2020
Chart Sales Price of FuKeWei (Anlotinib Hydrochloride of Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China, 2020
Chart Forecast on Sales Value of Anlotinib Hydrochloride in China, 2021-2025
Chart Forecast on Sales Volume of Anlotinib Hydrochloride in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  •  Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (FuKeWei®)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...